MedTrace Logo

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT02095132 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2023-09-26

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy (refractory). Adavosertib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Central Nervous System Embryonal Tumor With Rhabdoid Features
  • Central Nervous System Embryonal Tumor, Not Otherwise Specified
  • Central Nervous System Ganglioneuroblastoma
  • Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
  • Pineoblastoma
  • Primary Central Nervous System Neoplasm
  • Recurrent Childhood Central Nervous System Embryonal Neoplasm
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Medulloblastoma
  • Recurrent Neuroblastoma
  • Recurrent Rhabdomyosarcoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Medulloblastoma
  • Refractory Neuroblastoma
  • Refractory Rhabdomyosarcoma

Interventions

DRUG

Adavosertib

Given PO

DRUG

Irinotecan Hydrochloride

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Kristina A Cole · COG Phase I Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-28
Primary Completion
2020-12-31
Completion
2023-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02095132 on ClinicalTrials.gov